登录新浪财经APP 搜索【信披】查看更多考评等级 2020年6月30日，本公司与子公司南京安赛莱医药科技有限公司、广发银行股份有限公司扬州分行、中 国建设银行股份有限公司南京鼓楼支行和华泰联合证券签署《募集资金专户存储五方监管协议》,在广 发银行股份有限公司扬州分行开设募集资金专项账户(账号：9550880058239300203),在中国建设银行股 份有限公司南京鼓楼支行(建宁路支行)开设募集资金专项账户(账号：32050159524609999996)。 2020年6月30日，本公司与子公司扬州艾迪医药科技有限公司、江苏银行股份有限公司扬州分行和华泰 联合证券签署《募集资金专户存储四方监管协议》,在江苏银行股份有限公司扬州分行(唐城支行)开设募 集资金专项账户(账号：90160188000125327)。 2022年1月19日，公司召开第一届董事会第二十一次会议和第一届监事会第十七次会议，审议通过了 《关于变更部分募集资金专项账户及新增募集资金专项账户的议案》。 2022年1月26日，本公司与中国建设银行股份有限公司江苏省分行和华泰联合证券签署《募集资金专户 存储三方监管协议》,在中国建设银行股份有限公司 ...

Group 1: Shanghai Pudong Development Bank - The bank reported a net profit of 50.017 billion yuan for 2025, an increase of 10.52% year-on-year [1][2] - Total operating income reached 173.964 billion yuan, reflecting a growth of 1.88% compared to the previous year [2] - The bank's total assets exceeded 1 trillion yuan, reaching 1,008.1746 billion yuan, a 6.55% increase from the previous year [3] Group 2: Dongpeng Beverage - Dongpeng Beverage expects a net profit between 4.34 billion and 4.59 billion yuan for 2025, representing a year-on-year growth of 30.46% to 37.97% [4] - The anticipated operating income is projected to be between 20.76 billion and 21.12 billion yuan, indicating a growth of 31.07% to 33.34% [4] Group 3: TCL Technology - TCL Technology forecasts a net profit of 4.21 billion to 4.55 billion yuan for 2025, marking a significant increase of 169% to 191% year-on-year [5][6] - The company expects to surpass 100 billion yuan in operating revenue, with net profit exceeding 8 billion yuan [5] Group 4: Changjiang Electric Power - Changjiang Electric Power reported a net profit of 34.167 billion yuan for 2025, a 5.14% increase year-on-year [8] - The total operating revenue for the year is expected to be 85.882 billion yuan, reflecting a growth of 1.65% [8] Group 5: China Gold - China Gold anticipates a net profit of 286 million to 368 million yuan for 2025, a decrease of 55% to 65% year-on-year [21] - The decline is attributed to market fluctuations and reduced consumer traffic [21] Group 6: LaKala - LaKala expects a net profit between 1.06 billion and 1.2 billion yuan for 2025, representing a growth of 202% to 242% year-on-year [22] - The increase is primarily due to significant investment income from stock holdings [22] Group 7: Baiwei Storage - Baiwei Storage projects a net profit of 850 million to 1 billion yuan for 2025, indicating a year-on-year increase of 427% to 520% [23] - The growth is driven by improved sales and gross margins in the AI sector [23] Group 8: Shengxin Lithium Energy - Shengxin Lithium Energy forecasts a net loss of 600 million to 850 million yuan for 2025, similar to the previous year's loss [24] - The company attributes the loss to industry supply-demand dynamics and increased exchange losses [24] Group 9: Zhongguancun Online - Zhongguancun Online expects a net loss of 580 million to 700 million yuan for 2025, a significant increase from the previous year's loss of 243 million yuan [25] - The losses are linked to increased promotional investments in overseas markets [25] Group 10: Huaxia Happiness - Huaxia Happiness anticipates a net loss of 16 billion to 24 billion yuan for 2025, a substantial increase from the previous year's loss of 4.817 billion yuan [26] - The decline is due to reduced project turnover and high financial costs [26]

Core Viewpoint - The acquisition of an additional 22.2324% stake in Nanjing Nanda Pharmaceutical by Aidi Pharmaceutical strengthens its control and supports its integrated strategy in human-derived protein production and formulation [1][2]. Group 1: Acquisition Details - Aidi Pharmaceutical announced the acquisition of 22.2324% of Nanjing Nanda Pharmaceutical for 130.05954 million yuan, increasing its ownership from 51.1256% to 73.3580% [1]. - This acquisition is aimed at solidifying control and enhancing the implementation of the company's integrated strategy in human-derived protein [2]. Group 2: Strategic Benefits - The acquisition is expected to reinforce strategic management, enhance resource synergy, and improve operational efficiency by integrating production, channels, and platforms [2]. - The financial performance of Nanjing Nanda Pharmaceutical has shown steady growth, with revenues of 299 million yuan and net profits of 51.5177 million yuan in 2024, and 262 million yuan in revenue with net profits of 55.8111 million yuan from January to October 2025 [2]. Group 3: R&D Achievements - Following the previous acquisition, Aidi Pharmaceutical and Nanjing Nanda Pharmaceutical have successfully developed two human-derived protein drugs, AD108 and ADB116, which have received IND approval [3][4]. - These drugs are designed to meet clinical needs, with AD108 offering a subcutaneous delivery method and ADB116 providing a rapid intravenous administration option for acute ischemic stroke [4]. Group 4: Market Potential - The human-derived protein market, particularly for ischemic stroke treatment, is significant, with approximately 3.4 million new stroke cases annually in China, 80% of which are ischemic strokes [5]. - The market for ischemic stroke treatments is projected to grow, with a 2023 market size of approximately 12.9 billion yuan, indicating substantial opportunities for Aidi Pharmaceutical's new products [5]. Group 5: Future Outlook - Aidi Pharmaceutical plans to leverage this acquisition to deepen resource integration with Nanjing Nanda Pharmaceutical, accelerating the development of its human-derived protein pipeline [6]. - The company aims to capitalize on industry growth and enhance its position in the human-derived protein sector, contributing to high-quality development in the biopharmaceutical industry [6].

（文章来源：证券日报） 证券日报网讯 1月13日，艾迪药业发布公告称，公司基于总体工作安排，拟暂不召开股东会，后续将视 情况另行发布召开通知。 ...

Group 1: Company Announcements - Hongsheng Co., Ltd. has not generated revenue in the data center liquid cooling sector [1][2] - Oriental Pearl does not directly engage in AI business, and AI applications do not directly generate revenue [1][2] - Tongda Hai's AI-driven revenue accounts for a low proportion of the company's overall operating income [2] Group 2: Project Investments - Beibu Gulf Port plans to invest 11.403 billion yuan in the construction of a 300,000-ton terminal project in Fangcheng Port [1][2] - LeKai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film coating production line project [2] Group 3: Contract Awards - Aopt has won a bid for a 120 million yuan 2D vision solution project for GoerTek in 2026 [1][2] - Anhui Expressway has won a project worth 7.237 billion yuan [2] Group 4: Equity Transfers - Aidi Pharmaceutical intends to acquire a 22.2324% stake in Nanda Pharmaceutical for 130 million yuan [1][2] Group 5: Share Buybacks - Kaifa Electric plans to repurchase shares worth between 30 million and 60 million yuan [1][2] - Haojiang Intelligent plans to repurchase shares worth between 1.5 million and 3 million yuan [3] - Huazhi Jie plans to invest 30 million to 50 million yuan in share repurchases [3] Group 6: Shareholding Changes - New Work Group, a shareholder of China New Group, plans to reduce its stake by no more than 3% [3] - Zhejiang Yongqiang's shareholder plans to reduce his stake by no more than 1.13% [3] - Xiangyu Medical's shareholder plans to reduce his stake by no more than 3% [3]

Group 1 - The company, Jiangsu Aidi Pharmaceutical Group Co., Ltd., plans to raise up to 185 million yuan through a simplified procedure to issue A-shares, primarily to acquire a 22.23% stake in its subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., for approximately 130 million yuan, and to supplement working capital with 55 million yuan [1] - Nanda Pharmaceutical specializes in thrombolytic drugs and low molecular weight heparin raw materials, making it one of the few integrated manufacturers in China holding production approvals for both raw materials and injectable formulations [2] - The acquisition of Nanda Pharmaceutical is expected to enhance the company's control over it, optimize financial performance, and maximize synergies, thereby strengthening its competitive position in the human protein sector [3] Group 2 - The stroke incidence in China is rising, with acute ischemic stroke cases projected to increase from 4.1 million in 2023 to 4.9 million by 2027, highlighting a significant unmet clinical need for effective stroke treatments [3] - The market for neuroprotective drugs in China is expected to grow from 11.5 billion yuan in 2024 to 16.9 billion yuan by 2030, and further to 26.2 billion yuan by 2035, indicating a strong demand for innovative stroke medications [3] - Aidi Pharmaceutical has maintained rapid growth in the HIV sector for three consecutive years, with the market for anti-HIV drugs in China estimated at 7 billion yuan in 2023, projected to exceed 11 billion yuan by 2027 [4] Group 3 - The company is advancing its core HIV pipeline and aims to establish a comprehensive commercialization system for new HIV drugs, addressing the significant challenge posed by the large population of HIV-infected individuals in China [4] - Aidi Pharmaceutical has made significant progress in its HIV drug pipeline, with new drugs like ACC017 and ADC118 entering clinical trials, and is also developing long-acting pre-exposure prophylaxis drugs [5] - The 55 million yuan raised will be used to support operational funding and accelerate the development of core research projects, ensuring the efficient rollout of a diverse and comprehensive HIV drug commercialization strategy [5]

智通财经APP讯，艾迪药业(688488.SH)发布公告，公司拟以简易程序向特定对象发行A股股票，募集资 金总额不超过(含)1.85亿元，扣除发行费用后的募集资金净额将用于：收购南大药业22.2324%股权、补 充流动资金。 ...

艾迪药业(688488.SH)发布公告，公司拟以简易程序向特定对象发行A股股票，募集资金总额不超过 (含)1.85亿元，扣除发行费用后的募集资金净额将用于：收购南大药业22.2324%股权、补充流动资金。 ...

Core Viewpoint - The company, Aidi Pharmaceutical (688488.SH), plans to acquire a total of 22.2324% equity in its subsidiary, Nanda Pharmaceutical, from minority shareholders for a price of 130.05954 million yuan, enhancing its control and aligning with its strategic goals [1] Group 1: Acquisition Details - The company intends to purchase 19.6337% of Nanda Pharmaceutical's equity from Huatai Guoxin, 0.0987% from Daoxing Venture Capital, and 2.5000% from Yao Fandi [1] - The acquisition will be financed through the company's own or raised funds [1] Group 2: Strategic Implications - This acquisition will strengthen the company's control over Nanda Pharmaceutical, ensuring the steady implementation of its "human-derived protein raw materials - formulation integration" strategy [1] - Increasing the stake in Nanda Pharmaceutical is expected to enhance the company's performance, as the subsidiary has shown stable growth in revenue and profit in recent years [1]

格隆汇1月13日丨艾迪药业(688488.SH)公布2026年度以简易程序向特定对象发行A股股票预案，本次发 行募集资金总额不超过（含）18,500.00万元，符合以简易程序向特定对象发行股票的募集资金总额不超 过人民币三亿元且不超过最近一年末净资产百分之二十的规定；扣除发行费用后的募集资金净额将用于 以下项目：收购南大药业22.2324%股权、补充流动资金。 MACD金叉信号形成，这些股涨势不错！ ...